Clinical Trial Update: Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating omitting chemotherapy for ER-positive, HER2-negative breast cancer patients treated with ribociclib plus endocrine therapy; cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Yale University | Conditions: HER2 Negative Breast Cancer | Phase 2 | Status: RECRUITING